Chris Plummer

Dr Chris Plummer is a Senior Lecturer in the Institute of Cellular Medicine within Newcastle University's Faculty of Medical Sciences. With over two decades of research experience, his work bridges the critical intersection of cardiology and oncology, focusing on cardiovascular complications in cancer patients undergoing various treatments. His extensive publication record demonstrates significant contributions to understanding and mitigating cardiac risks associated with cancer therapies.

Dr Plummer's research primarily centers on cardio-oncology, investigating cardiovascular toxicity from cancer treatments, particularly chemotherapy and hormonal therapies. His work spans clinical trials, systematic reviews, and guideline development for monitoring cardiovascular health in cancer patients. Key areas include cardiomyopathy surveillance in cancer survivors, cardiovascular risk assessment in prostate cancer patients on hormonal therapy, and prevention of cardiac damage during breast cancer and lymphoma treatments.

Analysis of his recent publications reveals a consistent focus on improving clinical outcomes through evidence-based approaches. His work on the PROACT Clinical Trial addresses cardiac damage prevention, while his contributions to the International Late Effects of Childhood Cancer Guideline Harmonization Group have shaped surveillance protocols for cardiovascular complications in cancer survivors. His research often involves large collaborative efforts, demonstrating leadership in multi-institutional studies.

• Co-investigator on the PERSEPHONE trial examining optimal trastuzumab duration in breast cancer
• Contributor to European Cardiology guidelines and examinations
• Researcher in the ADMISSION collaborative studying multiple long-term conditions
• Investigator in clinical trials assessing novel cancer therapies and their cardiac implications

Dr Plummer's work has direct clinical applications, helping oncologists and cardiologists better manage the cardiovascular health of cancer patients. His dual expertise in cardiology and oncology positions him as a key contributor to the growing field of cardio-oncology, where his research helps balance effective cancer treatment with cardiovascular safety.